SITE008-0159

SITE008 (KOR) › SITE008-0159

SITE008-0159

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2026-03-12

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-09 (study day 174); relationship: not assessed

severe assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 107); relationship: NOT RELATED

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-25 (study day 70); relationship: NOT RELATED

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-15 (study day 60); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.